Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued to investors on Tuesday morning. The brokerage issued a sell rating on the stock.

Bio-Path Price Performance

BPTH opened at $0.87 on Tuesday. The business has a 50 day moving average of $0.89 and a 200-day moving average of $1.11. Bio-Path has a 1-year low of $0.59 and a 1-year high of $9.99.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC purchased a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent reporting period. Institutional investors and hedge funds own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.